January 30, 2023

Now Enrolling: The BRIDGE research study is evaluating a new treatment approach for patients with early bladder cancer

December 20, 2022

The November/December 2022 News from ECOG-ACRIN blog is now available

December 19, 2022

Blinatumomab Plus Consolidation Chemotherapy Significantly Reduces Risk of Death in MRD-Negative B-Cell ALL

December 15, 2022

Study E1910 consolidates the role of blinatumomab in acute lymphoblastic leukemia (ALL)

December 14, 2022

Blinatumomab further improves survival among patients with B-ALL and a good prognosis (study E1910)

December 13, 2022

Immunotherapy Plus Consolidation Chemo Improves Survival in B Lineage ALL

December 13, 2022

Blinatumomab regimen may lead to ‘diminishing use of transplant’ for B-ALL subgroup (study E1910)

December 13, 2022

Press Release: Practice-changing trial results for acute lymphoblastic leukemia (ALL)

December 11, 2022

Press Release: A unique clinical trial leads to a dramatic decrease in early deaths from the rare and aggressive—yet highly curable—acute promyelocytic leukemia (APL)

ECOG-ACRIN Cancer Research Group